AIM: Insulin and insulin-like growth factors (IGF's) are associated with an increased risk of colorectal adenomas. The association with recurrent adenomas is inadequately studied. We prospectively examined the relationship between insulin biomarkers and the risk of recurrent adenomas. MATERIALS AND METHODS: Our analysis included 167 subjects with one or more adenomas detected on a baseline colonoscopy who had a surveillance colonoscopy within three to five years. We measured serum biomarkers in all subjects at baseline. ELISA was used to measure fasting plasma insulin, IGF-I, IGF-II, and IGF binding protein-3. The hexokinase assay was used to measure fasting plasma glucose by and immuno-turbidimetric assay to measure hemoglobin A1C. RESULTS: Subjects with recurrent adenomas were more likely to be male, overweight and have ≥3 adenomas at baseline. We found no significant associations between insulin (OR=1.6, 95% CI 0.7-3.5), glucose (OR=1.4, 95% CI 0.7-3.1), IGF-I (OR=0.7, 95% CI 0.3-1.5), IGF-II (OR=1.0, 95% CI 0.5-2.3), IGFBP-3 (OR=0.1, 95% CI 0.5-2.1), or anthropometric measures and recurrent adenomas. CONCLUSION: Our results do not support a role for insulin biomarkers and recurrent colorectal adenomas.
AIM: Insulin and insulin-like growth factors (IGF's) are associated with an increased risk of colorectal adenomas. The association with recurrent adenomas is inadequately studied. We prospectively examined the relationship between insulin biomarkers and the risk of recurrent adenomas. MATERIALS AND METHODS: Our analysis included 167 subjects with one or more adenomas detected on a baseline colonoscopy who had a surveillance colonoscopy within three to five years. We measured serum biomarkers in all subjects at baseline. ELISA was used to measure fasting plasma insulin, IGF-I, IGF-II, and IGF binding protein-3. The hexokinase assay was used to measure fasting plasma glucose by and immuno-turbidimetric assay to measure hemoglobin A1C. RESULTS: Subjects with recurrent adenomas were more likely to be male, overweight and have ≥3 adenomas at baseline. We found no significant associations between insulin (OR=1.6, 95% CI 0.7-3.5), glucose (OR=1.4, 95% CI 0.7-3.1), IGF-I (OR=0.7, 95% CI 0.3-1.5), IGF-II (OR=1.0, 95% CI 0.5-2.3), IGFBP-3 (OR=0.1, 95% CI 0.5-2.1), or anthropometric measures and recurrent adenomas. CONCLUSION: Our results do not support a role for insulin biomarkers and recurrent colorectal adenomas.
Authors: A G Renehan; J E Painter; D O'Halloran; W S Atkin; C S Potten; S T O'Dwyer; S M Shalet Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: Koji Okabayashi; Hutan Ashrafian; Hirotoshi Hasegawa; Jae-Hoon Yoo; Vanash M Patel; Leanne Harling; Simon P Rowland; Mariam Ali; Yuko Kitagawa; Ara Darzi; Thanos Athanasiou Journal: Am J Gastroenterol Date: 2012-06-26 Impact factor: 10.864
Authors: John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk Journal: N Engl J Med Date: 2003-03-06 Impact factor: 91.245
Authors: Jutta M Nagel; Jürgen Staffa; Ingrid Renner-Müller; David Horst; Michael Vogeser; Markus Langkamp; Andreas Hoeflich; Burkhard Göke; Frank T Kolligs; Christos S Mantzoros Journal: Horm Cancer Date: 2010-12 Impact factor: 3.869
Authors: Adelheid Soubry; Dora Il'yasova; Rebecca Sedjo; Frances Wang; Tim Byers; Clifford Rosen; Anatoli Yashin; Svetlana Ukraintseva; Steven Haffner; Ralph D'Agostino Journal: Int J Cancer Date: 2011-09-14 Impact factor: 7.396
Authors: Andrew Flood; Volker Mai; Ruth Pfeiffer; Lisa Kahle; Alan T Remaley; Elaine Lanza; Arthur Schatzkin Journal: Gastroenterology Date: 2007-08-21 Impact factor: 22.682
Authors: Elizabeth T Jacobs; María Elena Martínez; David S Alberts; Erin L Ashbeck; Susan M Gapstur; Peter Lance; Patricia A Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-02-04 Impact factor: 4.254
Authors: G C Kabat; M Y Kim; H D Strickler; J M Shikany; D Lane; J Luo; Y Ning; M J Gunter; T E Rohan Journal: Br J Cancer Date: 2011-11-29 Impact factor: 7.640
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastroenterology Date: 2020-02-07 Impact factor: 22.682
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Gastrointest Endosc Date: 2020-02-07 Impact factor: 9.427
Authors: Samir Gupta; David Lieberman; Joseph C Anderson; Carol A Burke; Jason A Dominitz; Tonya Kaltenbach; Douglas J Robertson; Aasma Shaukat; Sapna Syngal; Douglas K Rex Journal: Am J Gastroenterol Date: 2020-03 Impact factor: 12.045